Q-omics provides the consensus-scored SRCIN1 profile across patient tissues and cancer cell-line models. SRCIN1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SRCIN1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, SRCIN1 protein abundance shows 24,685 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, THCA, and GBM as cancer lineages where SRCIN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRCIN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRCIN1 survival associations across molecular data types. SRCIN1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRCIN1 RNA expression–survival associations across cancer types. High SRCIN1 expression shows unfavorable associations in UVM, ACC, KIRC, UCEC and MESO, but favorable associations in BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SRCIN1 RNA expression.
This table summarizes SRCIN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SRCIN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRCIN1 shows higher tumor expression in THCA, KIRP, COAD, LUAD, LIHC and BLCA. The THCA box plot shows higher SRCIN1 RNA expression in tumor versus normal tissue (log2 FC = +2.387, t-test p < 0.001).
This table shows molecular features associated with SRCIN1 in patient tissues and cancer cell lines. In patient samples, SRCIN1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SRCIN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
